US4117131A - Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides - Google Patents

Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides Download PDF

Info

Publication number
US4117131A
US4117131A US05/832,312 US83231277A US4117131A US 4117131 A US4117131 A US 4117131A US 83231277 A US83231277 A US 83231277A US 4117131 A US4117131 A US 4117131A
Authority
US
United States
Prior art keywords
amino
pyrimidinyl
methyl
compound
thio
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/832,312
Inventor
Charles F. Schwender
Russell E. Pike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Application granted granted Critical
Publication of US4117131A publication Critical patent/US4117131A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine

Definitions

  • the present invention relates to the following generic series of compounds: ##STR1## wherein R 1 and R 2 are selected from a group consisting of hydrogen, amino, alkylamino, hydroxyl, alkyl or alkoxy; wherein R 3 and R 4 are selected from a group consisting of hydrogen, alkyl, alkoxy, amino, alkylamino, halogen, hydroxy, methylenedioxy, phenoxy, phenyl, alkylthio, trifluoromethyl, alkylsulfonyl and alkylsulfinyl; wherein m is 1-4, n is 0-4, and X is S or O. Also includes within the scope of the present invention are the pharmaceutically acceptable salts.
  • alkyl and alkoxy refer to those chemical moieties containing 1 to 4 carbon atoms in either straight or branched configuration;
  • halogen refers to fluoride, chloride, iodide, bromide, or iodide radicals.
  • the compounds of this invention may be prepared in two steps from readily available starting materials.
  • the appropriately substituted 4-chloro-pyrimidine is reacted with 2-mercaptoacetate in an alcohol containing sodium alkoxide as base to give the intermediate 2-(4-pyrimidinyl)-thioacetate.
  • Reaction of the acetate intermediate with the appropriate amine gives the desired compounds. ##STR2##
  • the analogs may also be prepared from the appropriately substituted 4-mercaptopyrimidine and the ⁇ -haloalkanoate ester in an alcohol containing an alkoxide as base.
  • the intermediate ester obtained is then reacted with the appropriate amine giving the compounds of this invention.
  • a pharmaceutical composition comprising a compound of formula I as has been defined or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
  • the pharmaceutically acceptable salts of the free compounds of general formula I may be prepared by conventional reactions with equivalent amounts of inorganic or organic acid solutions.
  • pharmaceutically acceptable salts there are the salts of hydrochloric, hydrobromic, sulfuric, benzenesulphonic, acetic, oxalic, malic, and citric acids.
  • the compounds of general formula I may be administered enterally or parenterally in admixture with a liquid or solid pharmaceutical diluent or carrier.
  • a liquid or solid pharmaceutical diluent or carrier As injection medium it is preferred to use water which contains the conventional pharmaceutical advantages for injection solutions such as stabilizing agents, solubilizing agents and buffers, for example, ethanol, complex-forming agents such as ethylene diamine tetraacetic acid, tartrate, and citrate buffers and highly molecular weight polymers such as polyethylene oxide for viscosity regulation.
  • carrier materials include starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids such as stearic acid, and high molecular weight polymers such as polyethylene glycols.
  • Oral forms of administration may, of course, contain flavoring, sweetening, preserving, suspending, thickening, or emulsifying agents.
  • a particular aspect of the formula composition comprises a compound of formula I in an effective unit dose form.
  • effective unit dose is meant a predetermined amount sufficient to be effective to bring about the desired decrease in gastric acid secretion in vivo.
  • a method of inhibiting gastric acid secretion in mammals comprising the administration of an effective secretion inhibiting amount of a compound of general formula I or a pharmaceutically acceptable salt thereof.
  • the compounds of this invention having the generic structure above, have been found to reduce gastric acid secretion response due to 4-methylhistamine, an H 2 -agonist when tested in accordance with the procedures of Shay (Gastroenterology 5:43, 1945) and Grossman (Gastroenterology 38:343, 1960).
  • the compounds are active when administered orally and parenterally in mammals such as rats and dogs throughout a dosage range of 0.05 - 20 mg/kg.
  • the compounds of this invention have been found not to act by an anticholinergic mechanism and therefore side effects observed in currently used therapy such as dryness of mouth or blurred vision does not occur.
  • the compounds of this invention are useful in the management and treatment of gastric hyperacidity.
  • the compounds of this invention are suitably and generally administered in oral dosage form, such as by tablet or capsule, by combining the same in an effective amount with any oral pharmaceutically acceptable inert diluent, such as lactose, starch, dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar.
  • any oral pharmaceutically acceptable inert diluent such as lactose, starch, dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar.
  • suitable binders, lubricants, disintegrating agents, and coloring agents can also be added.
  • Typical binders include starch, gelatin, sugars such as sucrose, molasses, and lactose, natural and synthetic gums such as acacia sodium alginate, extract of Irish moss, carboxymethyl cellulose, methylcellulose, and polyvinylpyrrolidone, polyethylene glycol, ethylcellulose, and waxes.
  • Typical lubricants for use in these dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, and polyethylene glycol.
  • Suitable disintegrators can include, without limitation, starch, methyl cellulose, agar, bentonite, cellulose and wood products, alginic acid, guar gum, citris pulp, carboxymethyl cellulose, and sodium lauryl sulfate. If desired, conventionally pharmaceutically acceptable dyes such as any of the standard FD & C dyes may be incorporated into the dosage unit form.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

2-(4-Pyrimidinyl)thioacetamides are disclosed that have been found useful in the treatment of gastric hyperacidity.

Description

This application is a continuation-in-part of U.S. Patent Application Ser. No. 748,348, filed Dec. 7, 1976, now abandoned.
The present invention relates to the following generic series of compounds: ##STR1## wherein R1 and R2 are selected from a group consisting of hydrogen, amino, alkylamino, hydroxyl, alkyl or alkoxy; wherein R3 and R4 are selected from a group consisting of hydrogen, alkyl, alkoxy, amino, alkylamino, halogen, hydroxy, methylenedioxy, phenoxy, phenyl, alkylthio, trifluoromethyl, alkylsulfonyl and alkylsulfinyl; wherein m is 1-4, n is 0-4, and X is S or O. Also includes within the scope of the present invention are the pharmaceutically acceptable salts.
As used above, the terms alkyl and alkoxy refer to those chemical moieties containing 1 to 4 carbon atoms in either straight or branched configuration; the term halogen refers to fluoride, chloride, iodide, bromide, or iodide radicals.
The preferred species of this invention includes those analogs where
R1 = nh2, r2 = ch3, r3 r4 = h and m = 1, n = 2
R1 = nh2, r2 = ch3, r3 = 4--och3, r4 = h, m = 1, n = 2
R1 = nh2, r2 = ch3, r3 r4 = h, m = 1, n = 1
R1 = nh2, r2 = ch3, r3 = 4--ch3, r4 = h, m = 1, n = 2
The compounds of this invention may be prepared in two steps from readily available starting materials. The appropriately substituted 4-chloro-pyrimidine is reacted with 2-mercaptoacetate in an alcohol containing sodium alkoxide as base to give the intermediate 2-(4-pyrimidinyl)-thioacetate. Reaction of the acetate intermediate with the appropriate amine gives the desired compounds. ##STR2##
The analogs may also be prepared from the appropriately substituted 4-mercaptopyrimidine and the ω-haloalkanoate ester in an alcohol containing an alkoxide as base. The intermediate ester obtained is then reacted with the appropriate amine giving the compounds of this invention. ##STR3##
In another aspect of the invention, there is provided a pharmaceutical composition comprising a compound of formula I as has been defined or a pharmaceutically acceptable salt thereof together with a pharmaceutically acceptable carrier.
The pharmaceutically acceptable salts of the free compounds of general formula I may be prepared by conventional reactions with equivalent amounts of inorganic or organic acid solutions. As exemplary of pharmaceutically acceptable salts there are the salts of hydrochloric, hydrobromic, sulfuric, benzenesulphonic, acetic, oxalic, malic, and citric acids.
The compounds of general formula I, as well as their pharmaceutically acceptable inorganic and organic acid salts, may be administered enterally or parenterally in admixture with a liquid or solid pharmaceutical diluent or carrier. As injection medium it is preferred to use water which contains the conventional pharmaceutical advantages for injection solutions such as stabilizing agents, solubilizing agents and buffers, for example, ethanol, complex-forming agents such as ethylene diamine tetraacetic acid, tartrate, and citrate buffers and highly molecular weight polymers such as polyethylene oxide for viscosity regulation. Examples of carrier materials include starch, lactose, mannitol, methylcellulose, talc, highly dispersed silicic acids, high molecular weight fatty acids such as stearic acid, and high molecular weight polymers such as polyethylene glycols. Oral forms of administration may, of course, contain flavoring, sweetening, preserving, suspending, thickening, or emulsifying agents.
A particular aspect of the formula composition comprises a compound of formula I in an effective unit dose form. By "effective unit dose" is meant a predetermined amount sufficient to be effective to bring about the desired decrease in gastric acid secretion in vivo.
In yet a further aspect of the invention, there is provided a method of inhibiting gastric acid secretion in mammals, including man, which comprises the administration of an effective secretion inhibiting amount of a compound of general formula I or a pharmaceutically acceptable salt thereof.
It is believed that one of ordinary skill in the art, can, using the preceding description, utilize the present invention to its fullest extent. The following specific embodiments, are, therefore, to be simply construed as merely illustrative and not to limit the remainder of the specification and claims in any way whatsoever.
EXAMPLE 1 Ethyl 2-[(2-amino-6-methylpyrimidin-4-yl)thio]acetate
Sodium (4.6 g, 0.2 mol) was dissolved in 1 l. abs. EtOH. Ethyl mercaptoacetate (24 g, 0.2 mol) was added and the resultant mixture was stirred 1 hr. at room temperature. The 2-amino-4-chloro-6-methylpyrimidine (0.2 mol) was added and the mixture was heated at reflux for 18 hrs. The reaction mixture was evaporated to a syrupy residue which was portitioned between CHCl3 (1.5 l.) and H2 O (100 ml). The CHCl3 phase was dried (MgSO4) and evaporated to give the crude product as an oil, 40.6 g (91%). The straw colored oil crystallized upon standing, m.p. 65°-69°. The analytical sample was obtained by a recrystallization from cyclohexane, 27 g (60%), m.p. 71°-73°.
EXAMPLE 2 2-[(2-Amino-6-methyl-4-pyrimidinyl)thio]-N-(2-phenylethyl)acetamide
A mixture of 7.50 g (33.0 mmol) of ethyl 2-[(2-amino-6-methylpyrimidin-4-yl)thio]acetate, 4.40 g (36.3 mmol) of 2-phenylethylamine and 25 ml of MeOH was heated at 120° for 18 hrs. in a steel bomb. The reaction mixture was evaporated to a residual solid which yielded crude solid product (7.65 g, 76.7%), m.p. 114°-121° upon trituration with Et2 O. The analytically pure sample was obtained after one recrystallization from 2-propanol, m.p. 130°-132° (3.79 g, 38%).
EXAMPLE 3 Butyl 5-[(2-amino-6-methyl-4-pyrimidinyl)thio]valerate
To a solution of sodium (1.79 g, 77.9 mmol) dissolved in 500 ml of 1-buOH, was added 10.0 g (70.8 mmol) of 2-amino-4-methyl-6-mercaptopyrimidine and the resultant mixture was stirred at room temperature for 1/2 hour. After the addition of ethyl 5-bromovalerate (29.7 g, 142 mmol), the mixture was heated at reflux for 20 hrs. The mixture was then evaporated to a residual oil which was suspended between 1N HCl (500 ml) and ether (500 ml). The acidic phase was basified with NH4 OH and extracted with CHCl3 (1 l.). The CHCl3 phase was dried (MgSO4) and evaporated to give 16.8 g (79.6%) of a straw colored oil which solidified upon standing, m.p. 45°-47°. One recrystallization from hexane gave the analytical ester; yield, 11.1 g (52.6%), m.p. 50°-52°.
The various physical properties of the preferred compounds of this invention are tabulated in the following Table I:
              TABLE I                                                     
______________________________________                                    
                                        Solvent                           
R.sub.1                                                                   
     R.sub.2                                                              
            n      R.sub.3                                                
                          R.sub.4                                         
                                 mp° C                             
                                        Recrystal                         
______________________________________                                    
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      H      H      130 - 32                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            3      H      H      149 - 51                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      4-Cl   H      168 - 70                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      4-NH.sub.2                                             
                          H      196 - 97                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      4-CH.sub.3                                             
                          H      178 - 79                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      3-OCH.sub.3                                            
                          4-OCH.sub.3                                     
                                 141 - 42                                 
                                        CH.sub.3 CN                       
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      4-OCH.sub.3                                            
                          H      147 - 49                                 
                                        CH.sub.3 CN                       
NH.sub.2                                                                  
     CH.sub.3                                                             
            2      3-Cl   H      111 - 12                                 
                                        CH.sub.3 CN                       
NH.sub.2                                                                  
     CH.sub.3                                                             
            1      H      H      164 - 65                                 
                                        2-PrOH                            
NH.sub.2                                                                  
     CH.sub.3                                                             
            1      4-Cl   H      192 - 94                                 
                                        CH.sub.3 CN                       
NH.sub.2                                                                  
     CH.sub.3                                                             
            1      4-OCH.sub.3                                            
                          H      152 - 53                                 
                                        CH.sub.3 CN                       
 ##STR4##            135 - 37 C.sub.6 H.sub.5 CH.sub.3                    
 ##STR5##             50 - 52 C.sub.6 H.sub.14                            
 ##STR6##             71 - 73 C.sub.6 H.sub.12                            
______________________________________
The compounds of this invention having the generic structure above, have been found to reduce gastric acid secretion response due to 4-methylhistamine, an H2 -agonist when tested in accordance with the procedures of Shay (Gastroenterology 5:43, 1945) and Grossman (Gastroenterology 38:343, 1960). The compounds are active when administered orally and parenterally in mammals such as rats and dogs throughout a dosage range of 0.05 - 20 mg/kg. The compounds of this invention have been found not to act by an anticholinergic mechanism and therefore side effects observed in currently used therapy such as dryness of mouth or blurred vision does not occur. The compounds of this invention are useful in the management and treatment of gastric hyperacidity.
As stated earlier, the compounds of this invention are suitably and generally administered in oral dosage form, such as by tablet or capsule, by combining the same in an effective amount with any oral pharmaceutically acceptable inert diluent, such as lactose, starch, dicalcium phosphate, calcium sulfate, kaolin, mannitol and powdered sugar. In addition, when required, suitable binders, lubricants, disintegrating agents, and coloring agents can also be added. Typical binders include starch, gelatin, sugars such as sucrose, molasses, and lactose, natural and synthetic gums such as acacia sodium alginate, extract of Irish moss, carboxymethyl cellulose, methylcellulose, and polyvinylpyrrolidone, polyethylene glycol, ethylcellulose, and waxes. Typical lubricants for use in these dosage forms can include, without limitation, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, and polyethylene glycol. Suitable disintegrators can include, without limitation, starch, methyl cellulose, agar, bentonite, cellulose and wood products, alginic acid, guar gum, citris pulp, carboxymethyl cellulose, and sodium lauryl sulfate. If desired, conventionally pharmaceutically acceptable dyes such as any of the standard FD & C dyes may be incorporated into the dosage unit form.
From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and without departing from the spirit and scope thereof can make various changes and/or modifications to the invention for adapting it to various usages and conditions. Accordingly, such changes and modifications are probably intended to be within the full range of equivalents of the following claims.

Claims (11)

We claim:
1. A method of inhibiting gastric acid secretions in a mammal which comprises the administration to a mammal of a pharmaceutical composition comprising a compound of the formula: ##STR7## wherein R1 and R2 are selected from the group consisting of hydrogen, amino, alkylamino, hydroxyl, alkyl, and alkoxy; wherein
R3 and R4 are selected from the group consisting of: hydrogen, alkyl, alkoxy, amino, alkylamino, halogen, hydroxy, methylenedioxy, phenoxy, phenyl, alkylthio, trifluoromethyl, alkylsulfonyl, and alkylsulfinyl;
wherein m is 1 to 4 methylenes; wherein n is 0 to 4 methylenes; wherein X is O or S; wherein alkyl and alkoxy are defined as having 1 to 4 carbon atoms; and the pharmaceutically acceptable salts thereof in an amount sufficient to decrease gastric acid secretions in said mammal.
2. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-phenethyl-acetamide.
3. The method according to claim 1 wherein the compound is 2-[2-amino-6-methyl-4-pyrimidinyl)thio]-N-(3-phenylpropyl)acetamide.
4. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[2-(4-methylphenyl)ethyl]acetamide.
5. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-2-pyrimidinyl)thio]-N-[2-(4-methoxyphenyl)ethyl]acetamide.
6. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[2-(3,4-dimethoxyphenyl)ethyl]acetamide.
7. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[(4-chlorophenyl)methyl]acetamide.
8. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[(4-methoxyphenyl)methyl]acetamide.
9. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-(phenylmethyl)acetamide.
10. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[2-(4-aminophenyl)ethyl]acetamide.
11. The method according to claim 1 wherein the compound is 2-[(2-amino-6-methyl-4-pyrimidinyl)thio]-N-[2-(4-chlorophenyl)ethyl]acetamide.
US05/832,312 1976-12-07 1977-09-12 Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides Expired - Lifetime US4117131A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74834876A 1976-12-07 1976-12-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US74834876A Continuation-In-Part 1976-12-07 1976-12-07

Publications (1)

Publication Number Publication Date
US4117131A true US4117131A (en) 1978-09-26

Family

ID=25009078

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/832,312 Expired - Lifetime US4117131A (en) 1976-12-07 1977-09-12 Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides

Country Status (1)

Country Link
US (1) US4117131A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224327A (en) * 1978-02-02 1980-09-23 Poli Industria Chimica S.P.A. 4-Pyrimidyl sulfides for the treatment of gastric ulcers
US4447441A (en) * 1981-03-09 1984-05-08 Imperial Chemical Industries Plc Haloalkylguanidine compounds, pharmaceutical compositions and methods, processes and intermediates
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4496564A (en) * 1981-03-09 1985-01-29 Ici Americas Inc. Amide derivatives
EP2322523B1 (en) * 2005-10-07 2019-01-02 Exelixis, Inc. Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898335A (en) * 1973-01-10 1975-08-05 Smithkline Corp Pharmaceutical compositions and methods of inhibiting gastric acid secretion
US3907814A (en) * 1972-08-28 1975-09-23 Smithkline Corp 2-Alkoxy(and 2-alkoxyalkyl)-2-pyridyl-thioacetamides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3907814A (en) * 1972-08-28 1975-09-23 Smithkline Corp 2-Alkoxy(and 2-alkoxyalkyl)-2-pyridyl-thioacetamides
US3898335A (en) * 1973-01-10 1975-08-05 Smithkline Corp Pharmaceutical compositions and methods of inhibiting gastric acid secretion

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224327A (en) * 1978-02-02 1980-09-23 Poli Industria Chimica S.P.A. 4-Pyrimidyl sulfides for the treatment of gastric ulcers
US4496567A (en) * 1978-11-13 1985-01-29 Smith Kline & French Laboratories Limited Phenyl alkylaminopyrimidones
US4447441A (en) * 1981-03-09 1984-05-08 Imperial Chemical Industries Plc Haloalkylguanidine compounds, pharmaceutical compositions and methods, processes and intermediates
US4496564A (en) * 1981-03-09 1985-01-29 Ici Americas Inc. Amide derivatives
EP2322523B1 (en) * 2005-10-07 2019-01-02 Exelixis, Inc. Process for the preparation of Pyridopyrimidinone Inhibitors of PI3Kalpha

Similar Documents

Publication Publication Date Title
US4161595A (en) Levulinic acid salt
US4929636A (en) Positive inotrophic benzothiazole and benzothiophene compositions and method of use therefor
JPS6354321A (en) Blood sugar lowering agent
JP3238397B2 (en) New sulfonyl compounds
US4147780A (en) α-Amino-phosphonous acids for inhibiting bacteria and yeast
US3639477A (en) Novel propoxyguanidine compounds and means of producing the same
US4261928A (en) 2-Benzoyl-8-(2-chloro-4-methoxyphenoxy)-1-phenyl-1-octanone
US4234725A (en) 4-[6-(2-Chloro-4-methoxyphenoxy)hexyl]-3,5-diethyl-1-[4-(4-morpholinyl)-1-oxobutyl]-1H-pyrazole
US4927835A (en) Acylphenol derivatives, useful as anti-inflammatory agents and pain suppressants
US5190961A (en) Thiourea derivatives and antimicrobial agent and antulcer agent containing the same
US4505921A (en) Sulfonylurea compounds and their use in treating diabetes
US4117131A (en) Method of inhibiting gastric acid secretions with 2-(4-pyrimidinyl)thioacetamides
US3637852A (en) 1-phenoxy-2-hydroxy-3-isopropylamino-propanes and salts thereof
AU601948B2 (en) 3-aminopropyloxyphenyl derivatives their preparation and pharmaceutical compositions containing them
AU617489B2 (en) Pyridazinone derivatives
KR950001040B1 (en) Thiourea derivatives and anti-microbial agent and antiulcer agent containing the same
JPH0153266B2 (en)
US4994484A (en) 1-(3-(2-hydroxy-3-alkylaminopropoxy)-2-thienyl)-3-phenyl-1-propanones and process for the preparation of the same
US4157340A (en) N,N'-[Bis(N-cyanoguanyl)]cystamine derivatives
JPH01250316A (en) Cholesterol-lowering agent
US4259334A (en) Piperazines and therapeutic utility
IE48912B1 (en) Alkylthiophenoxyalkylamines
US3992379A (en) 4-Alkyldioxyalkylene-5-benzylpyrimidines
US4010280A (en) Phenoxyalkylamine derivatives and preparation thereof
US4366157A (en) Novel polycyclic indole derivatives